دورية أكاديمية
[Appropriate Use and Abuse of Sedative-Hypnotic Drugs].
العنوان: | [Appropriate Use and Abuse of Sedative-Hypnotic Drugs]. |
---|---|
المؤلفون: | Zheng JW; National Institute on Drug Dependence, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University, Beijing 100191, China., Meng SQ; National Institute on Drug Dependence, Peking University, Beijing 100191, China., Liu WY; National Institute on Drug Dependence, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University, Beijing 100191, China., Chang XW; Peking University Sixth Hospital, Beijing 100191, China., Shi J; National Institute on Drug Dependence, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University, Beijing 100191, China. |
المصدر: | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition [Sichuan Da Xue Xue Bao Yi Xue Ban] 2023 Mar; Vol. 54 (2), pp. 231-239. |
نوع المنشور: | English Abstract; Journal Article; Review |
اللغة: | Chinese |
بيانات الدورية: | Publisher: Sichuan da xue xue bao (yi xue ban) bian ji bu Country of Publication: China NLM ID: 101162609 Publication Model: Print Cited Medium: Print ISSN: 1672-173X (Print) Linking ISSN: 1672173X NLM ISO Abbreviation: Sichuan Da Xue Xue Bao Yi Xue Ban Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Chengdu Shi : Sichuan da xue xue bao (yi xue ban) bian ji bu, 2003- |
مواضيع طبية MeSH: | Sleep Initiation and Maintenance Disorders*/drug therapy , COVID-19*, Humans ; Pandemics ; Hypnotics and Sedatives/adverse effects ; Sleep |
مستخلص: | The incidence of insomnia has been increasing in recent years. In addition, due to the impact of the COVID-19 pandemic, more and more people are experiencing a variety of insomniac problems, including having difficulty in sleep initation, waking up too early, and short sleep duration. Chronic insomnia may seriously affect patients' life and work, increase their risks of developing physical and mental illnesses, and cause crushing social and economic burdens. Sedative-hypnotics, including benzodiazepine agonists, melatonin receptor agonists, orexin receptor antagonists, and antidepressants with hypnotic effects, are widely used to treat most patients suffering from insomnia. However, there is the phenomenon of the non-medical use and abuse of sedative-hypnotic drugs, especially benzodiazepine receptor agonists. The abuse of sedative-hypnotic drugs may lead to mental and physical dependence, cognitive impairment, depression and anxiety, as well as an increased risks of falls and death. Therefore, drug regulatory authorities in China and other countries have issued relevant policies to reinforce regulation. Herein, we reviewed the prevalent use and safety of sedative-hypnotic drugs and proposed suggestions concerning their appropriate use. Both the efficacy and safety of sedative-hypnotic drugs should be carefully considered so that patients suffering from insomnia receive thorough and prompt treatment and the problem of potential abuse of sedative-hypnotic drugs is assessed in an objective and scientific manner. We also hope to provide references for the standardized clinical use of insomnia drugs. (Copyright© by Editorial Board of Journal of Sichuan University (Medical Sciences).) |
References: | Nat Neurosci. 2022 Mar;25(3):317-329. (PMID: 35228700) Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277. (PMID: 30722037) Br J Psychiatry. 2014 Nov;205(5):407-8. (PMID: 25061118) Addiction. 2003 Oct;98(10):1371-8. (PMID: 14519173) N Engl J Med. 2017 Mar 23;376(12):1147-1157. (PMID: 28328330) Addict Behav. 2021 Jan;112:106608. (PMID: 32861991) Therapie. 2020 Jul - Aug;75(4):343-354. (PMID: 32660776) Clin Neuropharmacol. 2014 Jan-Feb;37(1):6-8. (PMID: 24434525) PLoS One. 2021 Mar 4;16(3):e0247333. (PMID: 33661914) Pharmacol Res. 2016 Jul;109:92-100. (PMID: 26733466) Int J Environ Res Public Health. 2021 Jan 28;18(3):. (PMID: 33525737) Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109643. (PMID: 31071363) Pediatrics. 2020 Jul;146(1):. (PMID: 32581001) J Clin Neurol. 2019 Jan;15(1):9-19. (PMID: 30375757) Regul Toxicol Pharmacol. 2017 Jun;86:181-192. (PMID: 28279667) Drug Alcohol Depend. 2018 Nov 1;192:271-276. (PMID: 30300801) Drug Alcohol Depend. 2019 Feb 1;195:1-5. (PMID: 30553910) Psychiatr Prax. 2019 Oct;46(7):399-405. (PMID: 31412372) Eur Child Adolesc Psychiatry. 2022 Jul 6;:. (PMID: 35792937) Int Psychogeriatr. 2018 Jul;30(7):957-965. (PMID: 29559028) Subst Abus. 2021;42(3):377-387. (PMID: 32692942) Addict Behav. 2018 Dec;87:24-32. (PMID: 29940388) Lancet. 2022 Jul 16;400(10347):170-184. (PMID: 35843245) Joint Bone Spine. 2020 May;87(3):241-249. (PMID: 31778821) Br J Clin Pharmacol. 2021 Apr;87(4):1684-1694. (PMID: 32888191) Addict Behav. 2019 Jan;88:48-55. (PMID: 30142484) Clin Drug Investig. 2016 Jul;36(7):519-30. (PMID: 27056579) Am J Addict. 2018 Sep;27(6):485-490. (PMID: 30028048) BMC Psychiatry. 2015 Feb 19;15:28. (PMID: 25884573) Acta Psychiatr Scand. 2021 Aug;144(2):100-112. (PMID: 34021908) Am J Public Health. 2016 Apr;106(4):686-8. (PMID: 26890165) Br J Gen Pract. 2021 Oct 28;71(712):e877-e886. (PMID: 33950853) JAMA Netw Open. 2021 Oct 1;4(10):e2131012. (PMID: 34694388) J Clin Psychopharmacol. 2016 Aug;36(4):314-23. (PMID: 27253658) JAMA Psychiatry. 2022 Jul 1;79(7):710-717. (PMID: 35544235) Drug Alcohol Depend. 2014 Sep 1;142:105-9. (PMID: 25001277) Pharmacol Rev. 2018 Apr;70(2):197-245. (PMID: 29487083) Subst Use Misuse. 2015 Jan;50(2):148-55. (PMID: 25295596) BMJ Open. 2019 Jul 26;9(7):e029641. (PMID: 31350250) Nihon Rinsho. 2015 Jun;73(6):1049-56. (PMID: 26065141) JAMA Psychiatry. 2015 Feb;72(2):136-42. (PMID: 25517224) J Adolesc Health. 2018 Dec;63(6):709-716. (PMID: 30064889) J Adolesc Health. 2008 Dec;43(6):584-92. (PMID: 19027647) J Gen Intern Med. 2022 Jun;37(8):2103-2109. (PMID: 35415793) Pharmacol Rev. 2010 Mar;62(1):97-135. (PMID: 20123953) J Subst Abuse Treat. 1991;8(1-2):19-28. (PMID: 1675688) Nature. 2010 Feb 11;463(7282):769-74. (PMID: 20148031) Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18. (PMID: 22857878) PLoS Med. 2019 Nov 26;16(11):e1002965. (PMID: 31770388) BMC Psychiatry. 2016 Aug 04;16:274. (PMID: 27488186) Br J Clin Pharmacol. 2021 Apr;87(4):1676-1683. (PMID: 32472941) Br Med J (Clin Res Ed). 1982 Sep 18;285(6344):815-6. (PMID: 6126242) Lancet. 2022 Sep 24;400(10357):1047-1060. (PMID: 36115372) J Sleep Res. 2020 Aug;29(4):e13071. (PMID: 32406572) Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911. (PMID: 29244060) JAMA Netw Open. 2020 Jul 1;3(7):e2014053. (PMID: 32609353) Drug Alcohol Depend. 2019 Jul 1;200:95-114. (PMID: 31121495) Adv Pharmacol Sci. 2012;2012:416864. (PMID: 22536226) |
فهرسة مساهمة: | Keywords: Abuse; Addictiveness; Appropriate use; Insomnia; Safety; Sedative-hypnotic drugs |
المشرفين على المادة: | 0 (Hypnotics and Sedatives) |
تواريخ الأحداث: | Date Created: 20230323 Date Completed: 20230324 Latest Revision: 20230829 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC10409172 |
DOI: | 10.12182/20230260302 |
PMID: | 36949678 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1672-173X |
---|---|
DOI: | 10.12182/20230260302 |